Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% |
|
-.--% | -.--% |
06-20 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
06-18 | Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program | MT |
Sales 2024 * | 6.41M 5.73M 507M | Sales 2025 * | 7.39M 6.6M 585M | Capitalization | 15.15M 13.52M 1.2B |
---|---|---|---|---|---|
Net income 2024 * | -72M -64.29M -5.69B | Net income 2025 * | -44M -39.29M -3.48B | EV / Sales 2024 * | 5.71 x |
Net Debt 2024 * | 21.5M 19.2M 1.7B | Net Debt 2025 * | 78.9M 70.45M 6.24B | EV / Sales 2025 * | 12.7 x |
P/E ratio 2024 * |
-0.22
x | P/E ratio 2025 * |
-0.38
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.75% |
Latest transcript on Cara Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 05/08/18 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 11/09/22 |
Scott Terrillion
CMP | Compliance Officer | 61 | 31/10/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 30/06/10 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 15/07/14 |
Helen Boudreau
BRD | Director/Board Member | 58 | 01/08/23 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.22% | 93.91B | |
-1.32% | 38.4B | |
-13.44% | 32.61B | |
+76.30% | 28.2B | |
-13.11% | 15.91B | |
+0.68% | 14.22B | |
-12.06% | 11.54B | |
+185.28% | 10.74B | |
-53.00% | 9.47B |
- Stock Market
- Equities
- CARA Stock
- 69C Stock